Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

568
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
568
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.1K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.1K
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.1K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.1K
Seizures: Classification01:13

Seizures: Classification

1.2K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.2K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

762
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
762
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

829
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
829

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of care reorganisation during COVID-19 waves on non-COVID-19 inpatients in a Swiss hospital: a retrospective cohort study.

Swiss medical weekly·2026
Same author

The ICARUS project: study protocol for a randomised controlled trial Investigating aCute heArt failuRe decongestion guided by lung UltraSonography.

Trials·2026
Same author

[Selected novelties for hospital-based internal medicine].

Revue medicale suisse·2026
Same author

Response to the Letter to the Editor by Dr Koratala et al.

Canadian journal of kidney health and disease·2025
Same author

The widening gap between point-of-care ultrasonography course participation and supervision resources.

European journal of internal medicine·2025
Same author

Association between critical care occupancy and code status decisions during resource scarcity: a retrospective cohort study.

BMC medical ethics·2025
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

[Erythema multiforme : target deciphering].

Revue medicale suisse·2026
See all related articles

Related Experiment Video

Updated: Jan 3, 2026

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.3K

[Cefepime-induced encephalopathy].

Jennifer Muradbegovic1, Antonio Leidi1, Jacques Serratrice1

  • 1Service de médecine interne générale, HUG, 1211 Genève 14.

Revue Medicale Suisse
|November 29, 2019
PubMed
Summary
This summary is machine-generated.

A global shortage of piperacillin/tazobactam has led to increased use of cefepime. This broad-spectrum antibiotic can cause neurotoxicity, particularly in patients with kidney failure, but is often reversible.

More Related Videos

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement
06:58

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement

Published on: June 25, 2016

19.9K
Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats
08:47

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

11.9K

Related Experiment Videos

Last Updated: Jan 3, 2026

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.3K
Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement
06:58

Non-restraining EEG Radiotelemetry: Epidural and Deep Intracerebral Stereotaxic EEG Electrode Placement

Published on: June 25, 2016

19.9K
Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats
08:47

Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats

Published on: November 8, 2018

11.9K

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Nephrology

Background:

  • A worldwide shortage of piperacillin/tazobactam since 2017 has necessitated the use of alternative antibiotics.
  • Cefepime, a broad-spectrum antibiotic, has emerged as a common substitute.

Purpose of the Study:

  • To investigate the incidence and characteristics of cefepime-induced neurotoxicity.
  • To highlight diagnostic and management strategies for this adverse effect.

Main Methods:

  • Review of clinical data and literature concerning cefepime use and neurotoxicity.
  • Analysis of patient factors, particularly renal function, associated with neurotoxicity.
  • Correlation of cefepime serum concentrations and electroencephalogram findings with clinical presentation.

Main Results:

  • Up to 15% of patients treated with cefepime experienced neurotoxicity.
  • Neurotoxicity was more prevalent in patients with impaired kidney function.
  • Cefepime serum levels and EEG monitoring aided in diagnosis.

Conclusions:

  • Cefepime neurotoxicity is a significant concern, especially in renal impairment.
  • Dose adjustment or discontinuation of cefepime is the primary treatment.
  • Most patients recover fully without long-term neurological deficits.